JP2025526402A - 潰瘍性大腸炎及びクローン病治療のための抗ｔｌ１ａ抗体 - Google Patents

潰瘍性大腸炎及びクローン病治療のための抗ｔｌ１ａ抗体

Info

Publication number
JP2025526402A
JP2025526402A JP2025504350A JP2025504350A JP2025526402A JP 2025526402 A JP2025526402 A JP 2025526402A JP 2025504350 A JP2025504350 A JP 2025504350A JP 2025504350 A JP2025504350 A JP 2025504350A JP 2025526402 A JP2025526402 A JP 2025526402A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
administered
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025504350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025526402A5 (https=
Inventor
アレクサンドラ・クロポトヴァ
スタニスラフ・ストヤノフ
シャム・バスカーバイ・メータ
アンドリヤーナ・ラディヴォイェヴィッチ
Original Assignee
セファロン エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セファロン エルエルシー filed Critical セファロン エルエルシー
Publication of JP2025526402A publication Critical patent/JP2025526402A/ja
Publication of JP2025526402A5 publication Critical patent/JP2025526402A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2025504350A 2022-07-27 2023-07-27 潰瘍性大腸炎及びクローン病治療のための抗ｔｌ１ａ抗体 Pending JP2025526402A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263369591P 2022-07-27 2022-07-27
US63/369,591 2022-07-27
US202263387786P 2022-12-16 2022-12-16
US63/387,786 2022-12-16
PCT/US2023/071103 WO2024026395A1 (en) 2022-07-27 2023-07-27 Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease

Publications (2)

Publication Number Publication Date
JP2025526402A true JP2025526402A (ja) 2025-08-13
JP2025526402A5 JP2025526402A5 (https=) 2025-09-05

Family

ID=87747839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025504350A Pending JP2025526402A (ja) 2022-07-27 2023-07-27 潰瘍性大腸炎及びクローン病治療のための抗ｔｌ１ａ抗体

Country Status (12)

Country Link
US (1) US20250270336A1 (https=)
EP (1) EP4562040A1 (https=)
JP (1) JP2025526402A (https=)
KR (1) KR20250044336A (https=)
CN (1) CN119894931A (https=)
AU (1) AU2023314783A1 (https=)
CA (1) CA3262839A1 (https=)
CL (1) CL2025000202A1 (https=)
IL (1) IL318428A (https=)
MA (1) MA71621A (https=)
MX (1) MX2025001041A (https=)
WO (1) WO2024026395A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ＴＬ1ａ에 대한 항체 및 그의 용도
US9683998B2 (en) * 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
PL3774897T3 (pl) * 2018-04-30 2024-01-29 Cedars-Sinai Medical Center Sposoby i układ do selekcji i leczenia pacjentów z chorobami zapalnymi
AU2020275413A1 (en) * 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
WO2021034639A1 (en) * 2019-08-16 2021-02-25 Regeneron Pharmaceuticals, Inc. High concentration anti-c5 formulations
BR112022025667A2 (pt) 2020-06-26 2023-03-07 Pfizer Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a

Also Published As

Publication number Publication date
IL318428A (en) 2025-03-01
CN119894931A (zh) 2025-04-25
KR20250044336A (ko) 2025-03-31
CA3262839A1 (en) 2024-02-01
AU2023314783A1 (en) 2025-03-06
US20250270336A1 (en) 2025-08-28
EP4562040A1 (en) 2025-06-04
MX2025001041A (es) 2025-04-02
MA71621A (fr) 2025-05-30
WO2024026395A1 (en) 2024-02-01
CL2025000202A1 (es) 2025-07-11

Similar Documents

Publication Publication Date Title
US20240336691A1 (en) Anti-tl1a antibody compositions and methods of treatment in the lung
US20240309104A1 (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
CN105051064A (zh) 抗TNF-α抗原结合蛋白
JP2014524748A (ja) ＦｃＲｎ結合の増加したＴＮＦ−α抗原結合タンパク質
BR112013011176A2 (pt) métodos de tratamento de artrite reumatoide usando antagonistas de il-17
US20150291689A1 (en) Compositions and Methods for Treating Rheumatoid Arthritis
JP2020515577A (ja) 免疫原性の低下のための方法及び組成物
TW202330023A (zh) 異位性皮膚炎之治療
US20250270336A1 (en) Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
EP4665395A1 (en) Anti-tl1a antibody compositions and methods of treatment in the liver
JP2021523881A (ja) リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
US20250263494A1 (en) Anti-tl1a antibody formulations
WO2024173838A2 (en) Anti-tl1a antibody compositions and methods of treatment in the bile duct
EP4267184B1 (en) Interleukin 5 binding protein dosage regimen
KR20190024809A (ko) TNFα 관련 질환을 치료하는 방법
CN118524849A (zh) 用于治疗多血管炎、嗜酸性粒细胞增多综合症、伴有鼻息肉的慢性鼻窦炎嗜酸性粒细胞增多综合症(crswnp)或不伴有鼻息肉慢性鼻窦炎(crssnp)的白细胞介素5结合蛋白给药方案
EP4419562A1 (en) Aqueous formulations of an anti-cd22 antibody and uses thereof
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
CN116635417A (zh) 白介素5结合蛋白给药方案
JP2024539265A (ja) 製剤
WO2025217677A1 (en) Methods for treating neutrophilic skin conditions
WO2022136209A1 (en) Interleukin 5 binding protein dosage regimen
AU2023281062A1 (en) Methods and compositions for treating igg4- related diseases
KR20230025890A (ko) 인터루킨-17(il-17) 길항제를 이용한 갑상선 안병증 및 그레이브스 안와병증의 치료 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250827